Laboratory of Molecular Biochemistry, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.
Laboratory of Molecular Biochemistry, Department of Life Science, Faculty of Science, Gakushuin University, 1-5-1 Mejiro, Toshima-ku, Tokyo 171-8588, Japan.
Int J Mol Sci. 2020 May 27;21(11):3781. doi: 10.3390/ijms21113781.
The molecular pathology of diseases seen from the mitochondrial axis has become more complex with the progression of research. A variety of factors, including the failure of mitochondrial dynamics and quality control, have made it extremely difficult to narrow down drug discovery targets. We have identified MITOL (mitochondrial ubiquitin ligase: also known as MARCH5) localized on the mitochondrial outer membrane and previously reported that it is an important regulator of mitochondrial dynamics and mitochondrial quality control. In this review, we describe the pathological aspects of MITOL revealed through functional analysis and its potential as a drug discovery target.
从线粒体轴角度观察疾病的分子病理学随着研究的进展变得更加复杂。多种因素，包括线粒体动力学和质量控制的失败，使得缩小药物发现目标变得极其困难。我们已经确定了定位于线粒体外膜上的 MITOL（线粒体泛素连接酶：也称为 MARCH5），并之前报道过它是线粒体动力学和线粒体质量控制的重要调节剂。在这篇综述中，我们描述了通过功能分析揭示的 MITOL 的病理方面及其作为药物发现靶点的潜力。
Zotero 插件
